Date: September 28, 2026
KMP / Board / Auditor Changes
Not Specified
Dividend Declaration or Non-Declaration
Not Specified
Board Meeting Outcomes
Not Specified
Financial Results (Standalone & Consolidated)
The report provides the following consolidated financial highlights for FY2025-26:
- Revenue from Operations: ₹477.8 crore
- EBITDA: ₹53.7 crore
- EBITDA Margin: 11.24%
- Net Worth: ₹528.9 crore
Auditor’s Report
Not Specified
Disinvestment / Strategic Actions
Not Specified
Other Operational / Legal / Strategic Disclosures
- The company faced a significant safety incident at its Pashamylaram facility during the year, prompting comprehensive safety improvements.
- Independent assessments were conducted including PSCI (Pharmaceutical Supply Chain Initiative), TfS (Together for Sustainability), and SMETA (Sedex Members Ethical Trade Audit).
- A Life Cycle Assessment (LCA) of Microcrystalline Cellulose was completed to understand environmental impacts across the product life cycle.
- The company earned Great Place to Work® certification.
- Four CEP filings were made and Metformin CEP approval was granted by EDQM.
No material disclosures under the following sections:
- KMP / Board / Auditor Changes
- Dividend Declaration or Non-Declaration
- Board Meeting Outcomes
- Auditor's Report
- Disinvestment / Strategic Actions